You are here: Home » Markets » News
Business Standard

Pharma stocks on a roll, BSE Healthcare index hits new high

Sun Pharma, Ranbaxy, Cipla, Aurobindo and Biocon are up 1-3% on the Bombay Stock Exchange.

SI Reporter  |  Mumbai 

Pharmaceutical stocks continued their upward march with most frontline stocks trading at multi-year highs on the bourses.

Sun Pharmaceutical Industries, Ranbaxy Laboratories, Cipla, Aurobindo Pharma and Biocon are trading higher in the range of 1-3% on the Bombay Stock Exchange (BSE).

At 1025 hours, S&P BSE Healthcare index, the gauge of pharmaceutical companies, has surged 136 points or 1% to its record high of 12,067. In comparison, the S&P BSE Sensex declined 39 points at 26,061.

Sun Pharma (up 3.3% at Rs 744), Aurobindo (2.3% at Rs 787) and Cipla (2.2% at Rs 459) have touched their respective new highs, while Ranbaxy (up 2.6% at Rs 557) is trading at its highest level since November 2012.

Since June 26, Sun Pharma and Ranbaxy have rallied 18% each after USFDA granted approval to Ranbaxy's subsidiary Ohm Laboratories to manufacture and sell generic Diovan in the US. The benchmark index has gained 4% during the same period.

Meanwhile, analysts expect the pharmaceutical companies to post a strong revenue growth for the quarter ended June 2014 (Q1FY15), largely be driven by continued momentum in the US. Manoj Garg Research, an analyst at DSP Merrill Lynch expects growth momentum for the pharma companies to sustain with sales growth of 24%, EBITDA growth of 28% and profit after tax growth of 28% in 1QFY15 (April-June) over the previous year quarter.

"While revenue growth will largely be driven by continued momentum in the US, strong growth in the Rest of the World markets, higher currency realization (up 7% YoY; down 3% QoQ), 150 bps core margin expansion should drive net profit growth," he said in a client note.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, July 08 2014. 10:57 IST